PDSB PDS Biotechnology Corporation
Debt Financing ·
PDS Biotechnology amended a $6,000,000 note with YA II PN, Ltd. to require weekly remittances from at-the-market sales and to apply other equity proceeds to a mandatory redemption payment.
PDS Biotechnology approved a reduction in force on August 6, 2026 and estimates a one-time charge of approximately $842,000. It also ended Stephan Toutain's role as Chief Operating Officer.
Nasdaq said PDS Biotechnology's common stock closed below $1.00 for 30 consecutive business days. The letter has no immediate effect on its Nasdaq Capital Market listing, and the company names a reverse stock split as one option.
PDS Biotechnology's $6,000,000 note carries a 10% rate, a warrant for 2,158,274 shares and a twelve-month term. Yorkville Securities, an affiliate of the investor, is one of two sales agents for a $50,000,000 at-the-market program.
The 10% note matures in twelve months and is sold to YA II PN, LTD. for $5,760,000. It comes with a warrant for 2,158,274 shares at $1.1824 a share.
PDS Biotechnology sold $22,222,222 of senior secured convertible debentures for $20,000,000 on April 30, 2025, and used about $19 million to repay its Horizon Technology loan. The filing names no placement agent, underwriter, financial adviser or counsel.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $19.0 million | $22.6 million |
| Net income (loss) | -$34.5 million | -$37.6 million |
| Cash from operations | -$27.8 million | -$35.0 million |
| Cash and equivalents | $26.7 million | $41.7 million |
Our latest story on this, dated Jul 31, 2026: "PDS Biotechnology gets Nasdaq minimum bid price deficiency letter, has until January 26, 2027". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 31, 2026: "PDS Biotechnology amends $6,000,000 promissory note". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 2, 2025: "PDS Biotechnology sells convertible debentures for $20,000,000 to retire Horizon loan". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 31, 2026: "PDS Biotechnology gets Nasdaq minimum bid price deficiency letter, has until January 26, 2027". The story links the filing or release it is based on. Read the story.
PDS Biotechnology Corporation trades under the ticker PDSB on NASDAQ.
PDS Biotechnology Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:EU6; LS:A2PF3F; LSX:A2PF3F.
The SEC Central Index Key (CIK) for PDS Biotechnology Corporation is 1472091. Its filings are on SEC EDGAR.
55,971,338 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13.
Our directory records PDS Biotechnology Corporation under United States.
Our directory classifies PDS Biotechnology Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for PDS Biotechnology Corporation is US70465T1079.
aibio.space lists PDS Biotechnology Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
PDS Biotechnology Corporation reported a net loss of $34.5 million for the fiscal year ended Dec 31, 2025, and used $27.8 million of cash in operations, per its annual report to the SEC.
$19.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B4. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,3.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.03,3.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio